Allergan plc

This powerful committee controls taxation, trade, and entitlement spending (e.g., Medicare). Its decisions on corporate tax policy, international trade agreements, and Medicare drug pricing directly and significantly impact Allergan's profitability and market access.

This committee allocates discretionary federal spending. Its subcommittees determine funding for agencies like NIH (impacting research) and for healthcare programs (like VA or Medicare/Medicaid via other committees), directly affecting Allergan's market.

This committee directly regulates the FDA and NIH. Drug approval processes, oversight of pharmaceutical safety and efficacy, and funding for biomedical research are paramount to Allergan's R&D and market access.

This committee oversees antitrust laws and intellectual property, both critical to the pharmaceutical industry. Patent protection is vital for Allergan's branded products, and antitrust reviews impact M&A within the sector.

This committee investigates issues affecting older Americans, including drug pricing. Its hearings create significant 'headline risk' for pharmaceutical companies like Allergan and can drive legislative pressure on drug costs.